Bacterial infection of bone may result in bone destruction which is difficult to cure due to poor accessibility to bone of systemically-administrated antibiotic and poor performance of currently available local antibacterial treatments. PolyPid Ltd developed a novel local drug delivery system based on self-assembly of pharmaceutically approved lipids and polymers that encapsulate doxycycline (Doxy). The formulation is self-assembled lipid matrix via the interaction of the lipids (cholesterol and synthetic phospholipids) and biocompatible - biodegradable polymer (poly-lactic-co-glycolic). The entrapped Doxy is located within the anhydrous environment and therefore fully protected from both enzymatic and long-term water-exposure-related degradation. The fine coating of the tri-calcium phosphate (TCP) bone filler by this Doxy-containing formulation (BonyPid™) is capable of releasing intact and active drug at zero-order kinetics for a predetermined period of up to 30 days. The coating of the TCP granules with the polymer-lipids-Doxy formula (BonyPid™) did not change the granules’ macroscopic shape, but altered its color from white to pale yellow, which resemble the color of the entrapped Doxy. The average sizes of the non-coated TCP granules and the coated granules BonyPid™ were similar, as determined by measuring the widest dimension of each granule (1135±241 µm and 1072±242 µm, respectively, P=0.16). The MIC for Doxy that was released from BonyPid™ at different time points was similar to the non-encapsulated Doxy, suggesting full bioavailability of the released drug. BonyPid™ formulation structure was characterised by different physical methods including wide angle X-ray analyses (WAXS), differential scanning calorimetric (DSC) and SEM. WAXS analyses of BonyPid™ samples show a strong signal in the range of 1.3–1.8 2θ°, suggesting that the polymer and lipid TCP coating is a highly organised nano-substructure. The principle lipid in BonyPid™ formulation is phosphatidylcholine, which constitutes more than 85% of the overall lipid mass. It was found that the length of the acyl chains (14, 16 and 18 carbons, respectively) can significantly alter the release rate of Doxy during the prolonged (30 days), zero-order release phase, but did not alter the release profile. The anti-infection activity of BonyPid™ was tested in the rabbit tibia model contaminated with 5×105 Results demonstrate that BonyPid™ nan-technology that allow one month release of doxycycline in a controlled manner provides a new way for treating open fractures. This new local antibiotic delivery system is applicable in other medical situations associated with localised infections.Conclusion
Gustilo type III open fractures are associated with high infection rates in spite of instituting a standard of care (SOC) consisting of intravenous antibiotics, irrigation and debridement (I&D), and delayed wound closure. Locally-delivered antibiotic has been proven to assist in reducing infection in open fractures. The aims of this study are to determine the effectiveness and safety of a new implantable and biodegradable antibacterial product1 in preventing bacterial infections and initiating bone growth in open fractures. The osteoconductive antibacterial BonyPidTM used is a synthetic bone void filler (comprised of ≤1 mm β-tricalcium phosphate granules) coated by a thin layer (≤20 µm) of PolyPid nanotechnology formulation−. Upon implantation, the coating releases doxycycline at a constant rate for a predetermined period of 30 days. One BonyPidTM vial of 10 grams contains 65 mg of formulated doxycycline. After approval, sixteen subjects with Gustilo type III open tibia fractures, were implanted with the BonyPidTM immediately on the first surgical intervention (I&D), followed by external fixation. Patients had periodic laboratory, bacteriology and radiology follow-up.Purpose
Methods
Several hundred Joint Replacement Surgeries have been done by surgeons (Gustilo/Leagogo) of the Philippine Orthopedic Institute in the Philippines since its inception over 20 years ago. Revision surgery of failed cemented hip replacement, have been increasing in the last decade, which is the subject of this report. The average total cost of revision hip surgery in the Philippines ranges from PEP 800 000 to PEP 1 000 000 or USD 20 000 to USD 25 000. All medical records of the patients were reviewed to determine the following:
Etiology Duration from index surgery Common anatomical pathology and amount of leg length discrepancy encountered. Revision implants used and use of allograft. Postoperative course and complications Preliminary results (How many are ambulatory with or without assistive device). Analysis of x-ray at last follow-up. A total of sixty nine (69) patients were included in the study. Sixty eight percent (68%) of the patients (47 out of 69) underwent revision due to aseptic loosening of components (femoral or acetabular). Nine (9) patients (13%) developed infection. Six (6) patients (9%) developed protrusio acetabuli that necessitated revision. Peri-prosthetic fracture was noted in four (4) patients (6%). Three (3) patients had hip dislocation (4%) prior to revision. Average number of years from index surgery is 9 years (2–18years). Fifty nine (59) patients (86%) underwent cemented total hip prior to revision while ten (10) patients (14%) underwent cemented partial hip replacement prior to revision. Fifty six (56) patients (81%) have shortening on the affected side with an average of 3cm (1–6cm). Forty five (45) patients (65%) had proximal femoral bone loss requiring structural allograft. Thirty one (31) patients (45%) had acetabular defect (Paprosky Types I &
II). In sixty five (65) patients (94%), Active LockTM Cementless Hip Revision System was used. All patients were allowed full weight-bearing after revision surgery. Four patients (6%) developed acute post-op infection. Two patients (3%) had dislocation after revision surgery. At short-term follow-up of one year or more, only 5 patients were ambulating with assistive device. The rest are ambulatory, without aid and are symptom free. Follow-up radiographs showed implants in excellent alignment, no signs of loosening, migration or subsidence. The main reason for revision hip arthroplasty in the Philippines is aseptic loosening (68%) followed by infection (13 %). The use of long non-cemented, calcar-replacing curved revision stem, and strut allograft on the femoral side; jumbo, cementless acetabular socket and a high hip center on the acetabular side, addressed the problem of anatomic pathologies as a result of failed, cemented THR. There is no association between cause for revision with gender and age of the patients.
This technique would be particularly applicable when the surgeon would like to avoid the use of cement in a revision setting. The use of this method for uncemented revision Total Hip Arthroplasty should be studied further in a clinical setting before it is advocated for widespread use.